publication date: May. 2, 2018
Issue 18 - May. 2, 2018
  • Flatiron, BMS form collaboration to curate regulatory-grade real-world data

    Bristol-Myers Squibb and Flatiron Health announced a three-year collaboration to advance methodologies for the curation of real-world data for cancer research and to develop regulatory-grade information.

    BMS will use Flatiron data to analyze real-world evidence across a range of tumors and will collaborate on the development and validation of real-world endpoints within Flatiron’s longitudinal datasets.

  • Conversation with The Cancer Letter

    BMS’s Saha: We’re at the start of defining new endpoints, hypotheses with real-world evidence

    Bristol-Myers Squibb’s three-year collaboration with Flatiron Health will focus on leveraging real-world data to improve the pharmaceutical company’s regulatory submissions, demonstrate the economic value of BMS’s cancer portfolio, and to study the predictive value of biomarkers.

  • Conversation with The Cancer Letter

    Oklahoma’s Stephenson Cancer Center earns coveted NCI Cancer Center designation

    The Stephenson Cancer Center at the University of Oklahoma May 2 announced that it has received Cancer Center designation from NCI.

    This designation brings the total number of NCI designated cancer centers to 70. With Stephenson included, 14 of these centers now have the Cancer Center designation, 49 have the Comprehensive Cancer Center designation, and seven have the Basic Laboratory Cancer Center designation.

     

  • In Brief

    • National Coalition for Cancer Research to cease operations as member groups take on their own education, policy roles
    • Campaign to educate Washington, DC, public about clinical trials
  • Funding Opportunities

    CPRIT announces New Seed Award for early-stage oncology startups

    The Cancer Prevention and Research Institute of Texas is unveiling a new award mechanism targeting early-stage oncology startup companies. Under this program, known as the Seed Award, companies can apply for up to $3 million in nondilutive funding to support development of innovative cancer therapeutics, diagnostics or tools.

  • TCCL Logo

  • New data prompts CDC to examine adequacy of pre-op workup by gynecologists

    In response to a congressional letter and a new study on the prevalence of undiagnosed hidden uterine cancers, officials at the Centers for Disease Control and Prevention are considering launching a review of whether gynecologists are sufficiently thorough in evaluating patients in the preoperative setting, according to insiders with knowledge of the agency’s plans.

  • Clinical Roundup

    • Keytruda meets ORR endpoint in interim analysis of phase III trial in NSCLC
  • Drugs and Targets

    • Novartis’ Kymriah gets second FDA approval—for large B-cell lymphoma
    • FDA approves Tafinlar and Mekinist for BRAF V600-mutant melanoma
    • FDA grants priority review to cemiplimab in advanced cutaneous squamous cell carcinoma
    • Genocea files IND for neoantigen cancer vaccine candidate GEN-009
  • CTEP Protocols

    NCI Trials for May

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

Copyright (c) 2018 The Cancer Letter Inc.